Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Authors :: Groen, Kaz
Stege, Claudia A.M.
Nasserinejad, Kazem
de Heer, Koen
Van Kampen, Roel J.W.
Leijs, Maria B.L.
Thielen, Noortje
Westerman, Matthijs
Wu, Ka Lung
Ludwig, Inge
Issa, Djamila
Velders, Gerjo A.
Vekemans, Marie-Christiane
van de Donk, Niels W.C.J.
Timmers, Gert-Jan
Sonneveld, Pieter
Seefat, Maarten R.
Croon-de Boer, Fransien
Tick, Lidwine W.
van der Spek, Ellen
De Waal, Esther G.M.
Sohne, Maaike
Ypma, Paula F
Nijhof, Inger S.
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
Source :: Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p80-80, 1p
Publication Year :: 2021
Abstract: Introduction

Full Text Access

Tools